1. Aoki K, Nishito N, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Nishizawa T, Fukuda H, Ohashi K, Arai K, Mizoguchi Y, Yoshida Y, Watanabe S, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K,Niida S, Kanai Y, Hirayama A, Soga T, Maruyama T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Mizuno H, Tsunoda H, Ochiai A. Tumor-infiltrating lymphocyte profiling defines three immune subtypes of NSCLC with distinct signaling pathways and genetic alterations. Cancer Res Communications (in press)
2. Karayama M, Mizoguchi Y, Inoue Y, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suda T, Kitano S, Aoki K, Yamada Y. An increase in peripheral blood CD86-positive plasmacytoid dendritic cells is associated with immune-related adverse events after immune checkpoint inhibitor therapy in patients with non-small cell lung cancer. Global Health Med 4:301-308, 2022 doi: 10.35772/ghm.2022.01052
3. Zhang M, Kiyono T, Aok Ki, Goshima N, Kobayashi S, Hiranuma K, Shiraishi K, Saya H, Nakahara T. Development of an in vitro carcinogenesis model of HPV-induced cervical adenocarcinoma, Cancer Sci, 113; 904-915, 2022 doi: 10.1111/cas.15246.
4. Sawada J, Hiraoka N, Qi R, Jiang L, Fournier-Goss AE, Yoshida M, Kawashima H, Komatsu M. Molecular Signature of Tumor-Associated High Endothelial Venules That Can Predict Breast Cancer Survival. Cancer Immunol Res, 2022 10:468-481. doi: 10.1158/2326-6066.
5. Shirasawa M, Yoshida T, Imabayashi T, Okuma K, Matsumoto Y, Masuda K, Motoi N, et al. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. Eur J Cancer. 162:1-10, 2022. DOI: 10.1016/j.ejca.2021.11.013
6. Sugawara K, Fukuda T, Kishimoto Y, Oka D, Yoshii T, Hara H, Motoi N et al. Influences of intratumoral heterogeneity on assessment of tumor microenvironment in esophageal squamous cell carcinoma. Cancer Science. 114:1180-1191, 2023. doi.org/10.1111/cas.15665
7. Satoh H, Arai Y, Furukawa E, Moriguchi T, Hama N, Urushidate T, Totoki Y, Kato M, Yamamoto M, Shibata T. Genomic landscape of chemical-induced lung tumors under Nrf2 different expression levels. Carcinogenesis. 43: 613-520, 2022 doi: 10.1093/carcin/bgac041.